Join us for the HTRS/NASTH 2019 Scientific Symposium!
Visit www.2019Symposium.org for the full program!
May 9 - 11, 2019 -- Hilton New Orleans Riverside
This is the 11th Symposium of the Hemostasis and Thrombosis Research Society (HTRS), and the first where NASTH has partnered with us. Our organizations will bring together leading basic and translational science investigators with clinical colleagues for a dynamic meeting featuring:
- State-of-the-Art Lectures and Scientific Sessions covering a range of critical topics
- Collaboration and networking
- Social events including “An Evening at Mardi Gras” at the Float Den, where the city’s spectacular parade floats are created
- Oral Abstract Presentations and Poster Sessions featuring over 100 submitted abstracts
- Career Development Breakfasts for early career investigators
Active HTRS members receive discounted registration as a benefit of membership. Visit www.htrs.org to join or renew your membership today.
- Visit www.2019symposium.org; click on “Registration”
- If you're a Member, enter your Member Code
- Once entered, your Member Code will automatically apply the HTRS member discount to your registration
We look forward to seeing you in New Orleans!
With thanks to the HTRS/NASTH 2019 Symposium Sponsors, Exhibitors, and Medical Education Supporters to date:
Bayer, BPL, Cincinnati Children's Hospital, CSL Behring, Genentech, HTRS Members who Donated to the 2018 Annual Appeal, Octapharma, Pfizer, Sanofi Genzyme, Sebia, Takeda, Tremeau Pharmaceuticals, uniQure Inc.
Alnylam Pharmaceuticals, Bayer, BioMarin Pharmaceutical, BMS/Pfizer, BPL, CSL Behring, CSL Behring Medical Affairs, Foundation for Women and Girls with Blood Disorders, Genentech, Grifols USA, LLC, Hemophilia Alliance, Kedrion Biopharma Inc., Machaon Diagnostics, Novo Nordisk Inc., Pfizer, Red Chip Enterprises, Sanofi Genzyme, Takeda, Takeda Medical Affairs, Tremeau Pharmaceuticals, Versiti
Medical Education Grants
Bayer, CSL Behring, Genentech, Grifols USA, Inc., Pfizer, Portola Pharmaceuticals, Inc.
Apply for a Grant: FWGBD 2019 Research Awards
Application Deadline: 4.26.2019
Award Target: New Faculty or Fellows
SEE DETAILS BELOW
The Foundation for Women & Girls with Blood Disorders is pleased to announce the offering of two research award categories for 2019:
1) FWGBD Special Research Grant Award*
- Focus Area: Bleeding Disorders affecting women and girls
- Award Target: New Faculty or Fellows
- Number of Awards to be Given: 2
- Amount of the Award: $35,000
To learn more, click HERE
2) FWGBD Annual Research Award Grant
- Focus Area: Blood Disorders-all blood disorders affecting women and girls
- Award Target: New Faculty or Fellows
- Number of Awards to be Given: 1
- Amount of the Award: $15,000
To learn more, click HERE
The overall objectives of these awards are to:
- Create and sustain interest/knowledge of the next-generation of healthcare providers, i.e., physician-researchers working in beelding and other blood disorders affecting women/girls
- Foster collaboration between two core disciplines for WGBD: the hematologist and the obstetrician/gynecologist
- Provide an opportunity for junior faculty or fellows to conduct research in this important area
Application Due Date: April 26, 2019
* The offering of the Special Research Grant Award is made possible in part through an educational grant from Shire
Apply for a Grant
THSNA Travel-to-a-Mentor Award
2018 HTRS Annual Business Meeting
The 2018 HTRS Annual Business Meeting webinar and slides are available to HTRS members for viewing in the members-only section on the HTRS website. The annual meeting, entitled “HTRS Today,” was held on June 11, 2018 and covered an update of our growth and success, a review of where we are, and a preview of things to come.
Join a Registry
The Children’s Hospital-Acquired Thrombosis (CHAT) Study
HTRS Recognizes World Hemophilia Day: 4.17.2019
April 17 is World Hemophilia Day — a day to raise public awareness about hemophilia and recognize scientific advances in caring for patients and their families. World Hemophilia Day is celebrated on April 17 to coincide with the birthday of Frank Schnabel, a Montreal businessman born with hemophilia A, who founded the World Federation of Hemophilia (WFH) in 1963.
Significant advancements in the treatment of hemophilia have been realized over the past decade, giving both providers and patients new options for managing hemophilia and hemophilia with inhibitors. Long-acting clotting factors, novel non-factor replacement therapies, and emerging gene therapies can now produce positive, long-term results by reducing the number of required treatments and improving overall quality of life.
These new, longer-lasting therapies have the potential to affect change regarding the high cost and accessibility of hemophilia treatment. According to WFH, it is estimated that more than 400,000 people live with this bleeding disorder around the globe, and about 75% of those with the disease still receive inadequate treatment or have no access to treatment.
HTRS is proud of our member clinicians, physician scientists, and allied health professionals who are at the forefront of advancing care and treatment options for patients with blood disorders such as hemophilia. We hope everyone will recognize World Hemophilia Day this year with a donation of any amount to HTRS at www.htrs.org. Your tax deductible gift will support research, professional education, and workforce development for providers in hemophilia who are working every day to advance care and scientific knowledge of this rare blood disorder.
ASH seeking feedback on draft clinical practice guidelines: Deadline: Monday, May 13, 2019
The American Society of Hematology is seeking comments on draft clinical practice guidelines on sickle cell disease-related pain and cell disease-related transplantation.
Materials are available at www.hematology.org/Guidelines-Public-Comment. The deadline to comment is Monday May 13, 2019.
This comment period is open to all HTRS members, ASH members and the public. Feedback received will be provided to the guideline panels for review. Comments will also be considered during ASH organizational approval of the guidelines, peer review of the guidelines for journal publication, implementation and dissemination efforts following publication, and future revision efforts.
These guidelines were developed by ASH and supported by the Mayo Clinic Evidence-Based Practice Center, using a systematic process intended to meet recommendations of the Institute of Medicine. Recommendations were formed by guideline panels that include experts in SCD from multiple disciplines, methodologists, and patient representatives.
Please let your colleagues know about this public comment period. If you use social media, you may create your own tweet, using #ASHGuidelines.
Sample Tweet: New ASH guidelines on SCD are posted for comment! Add your feedback: https://tinyurl.com/y9qnz4ye #ASHGuidelines
Your feedback is essential to strengthen the content and credibility of the final guidelines. We thank you in advance for your participation.
HTRS Member Spotlight: Dr. Evi Stavrou, Oscar D. Ratnoff Professor of Medicine & Hematology, Case Western Reserve University
Dr. Evi X. Stavrou, Director of Anticoagulation Clinic at the Louis Stokes Cleveland VA Medical Center, received her MD degree summa cum laude from Semmelweis University in Budapest, Hungary. On completion of her medical school training, Dr. Stavrou completed her Internal Medicine residency at Johns Hopkins University-Sinai program and Hematology-Oncology fellowship at University Hospitals Case Medical Center. Presently, Dr. Stavrou’s work is focused on the Factor XII – uPAR interactome and neutrophil cell biology in health and disease. Her work has been published in premier journals including Blood, the Journal of Thrombosis and Haemostasis, Nature Communications and the Journal of Clinical Investigation. Dr. Stavrou’s work was funded initially through an HTRS Mentored Research Award supported with a grant from Baxter Healthcare Corporation (now Takeda) and subsequently from the American Heart Association. Presently, Dr. Stavrou is funded by the National Institutes of Health, VA Research & Education Foundation, and VA Advanced Platform Technology Center. Her clinical duties are focused solely on patients with hemostatic and thrombotic disorders.
Q&A: GETTING TO KNOW YOU
Q: Outside of medicine, what other interests do you pursue?
A: I am a classically trained violinist so I like to keep up, perhaps not as much as I’d hope. I also like to keep my orchids alive.
Q: If you could bring one book and movie to a desert island...
A: For a book, I would choose “The Undoing Project” by Michael Lewis because it illustrates how opposite geniuses attract and is a fantastic example of complementary collaboration among individuals. Amos and Danny completed each other scientifically to introduce the concept that psychology can be applied to Economics and human decision-making. They are a prime example that collaboration can lead to innovative thinking and a new field of science. It is also a wonderful testament to ever-lasting friendship and a sad story, as Amos passed away before receiving the Nobel Prize that he so much deserved.
For a movie on a desert island, I would pick “The Sound of Music.” I grew up watching it and I would need the happiness and music to remind me there are things to live for.
FOR COMPLETE INTERVIEW: CLICK HERE!